Real-life indications of finerenone in patients with heart failure with mildly reduced or preserved ejection fraction

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in for access options

Sign in to view the resources

About the speaker

Doctor Giulia Antonelli

Humanitas Research Hospital, Rozzano (Italy)

6 More presentations in this session

Presentation thumbnail

Prognostic value of hyperkalemia and mineralocorticoid receptor antagonist use in heart failure: a national registry study

Doctor K. Berge (Nordbyhagen, NO)

Presentation thumbnail

Temporal trends in mineralocorticoid receptor antagonist use among patients with heart failure in a community-based cohort

Doctor A. Ambrosy (San Francisco, US)

Presentation thumbnail

Finerenone: from evidence to clinical practice. Data from the finerlife registry (finerenone in real life)

Mr A. Hernandez Concepcion (Palmas de Gran Canaria, Las, ES)

Presentation thumbnail

SENEKA: a randomized clinical trial to optimize RAASi therapy using sodium zirconium cyclosilicate in elderly patients with heart failure and chronic kidney disease at risk of hyperkalemia

Doctor C. Bonanad Lozano (Valencia, ES)

Presentation thumbnail

Mineralocorticoid receptor antagonists in heart failure: real-world uptake, dose titration, hyperkalaemia trends, and potassium binder use

Doctor T. Furlan (Trbovlje, SI)

Access the full session

Session thumbnail

Mineralocorticoid receptor antagonists: from trials to real life

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

You may be interested in

Congress Presentation

Finerenone: from evidence to clinical practice. Data from the finerlife registry (finerenone in real life)

Congress Presentation

FINEARTS-HF - Finerenone in heart failure with mildly reduced and preserved ejection fraction

Congress Presentation

Finerenone in patients with severe heart failure: the FINEARTS-HF Trial

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources